A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects

NCT04184466 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-12-03

No results posted yet for this study

Summary

Pharmacokinetics and pharmacodynamics study of 2 formulations of insulin aspart (Insulin Aspart GEROPHARM vers. NovoRapid® Penfill® Novo Nordisk)

Conditions

  • Clamp Study

Interventions

DRUG

Insulin Aspart

insulin aspart in doses 0.3 IU/kg

DRUG

NovoRapid® Penfill®

insulin aspart in doses 0.3 IU/kg

Sponsors & Collaborators

  • Geropharm

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2018-12-19
Completion
2018-12-19

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184466 on ClinicalTrials.gov